| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | narciclasine | CTRPv2 | pan-cancer | AAC | -0.035 | 0.3 |
| mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.038 | 0.3 |
| mRNA | selumetinib:PLX-4032 (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.036 | 0.3 |
| mRNA | cediranib | CTRPv2 | pan-cancer | AAC | -0.058 | 0.3 |
| mRNA | ISOX | CTRPv2 | pan-cancer | AAC | -0.033 | 0.3 |
| mRNA | trifluoperazine | CTRPv2 | pan-cancer | AAC | -0.039 | 0.3 |
| mRNA | BRD-K42260513 | CTRPv2 | pan-cancer | AAC | -0.058 | 0.3 |
| mRNA | 5-FU | CTRPv2 | pan-cancer | AAC | -0.034 | 0.3 |
| mRNA | BRD-A02303741 | CTRPv2 | pan-cancer | AAC | -0.038 | 0.3 |
| mRNA | AZD1480 | CTRPv2 | pan-cancer | AAC | -0.055 | 0.3 |